BMRN News and Press, BioMarin Pharmaceutical Inc. From 11/01/23

2023-11-01 19:36:03 ET Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Conference Call November 01, 2023, 04:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Jean-Jacques Bienaime - Chairman and Chief Executive Officer Jeffrey Ajer -...

2023-11-01 16:29:22 ET More on BioMarin Pharmaceutical BioMarin: Growth Drivers Remain Intact BioMarin: Q2 2023 Confirmed My Bullish View BioMarin appoints Alexander Hardy as president and chief executive officer BioMarin Pharmaceutical Q3 2023 Earnings Previ...

2023-11-01 16:27:34 ET More on BioMarin Pharmaceutical BioMarin: Growth Drivers Remain Intact BioMarin: Q2 2023 Confirmed My Bullish View BioMarin Pharmaceutical Q3 2023 Earnings Preview Bernstein upgrades BioMarin to market perform, citing valuation ...

BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year PR Newswire • Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO ® and ROCTAVIAN ® ...

BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer PR Newswire Mr. Hardy Brings More than 30 Years of Industry Experience, Most Recently as CEO of Genentech Mr. Bienaim é Served as CE...

Hitachi Construction Machinery Co. Ltd ADR (HTCMY) is expected to report for Q2 2024 DigitalBridge Group Inc. (DBRG) is expected to report $0 for Q3 2023 LY Corp ADR (YAHOY) is expected to report for Q2 2024 DT Midstream Inc. (DTM) is expected to report $0.9 for Q3 2023 Summit Mat...

BioMarin Pharmaceutical Inc. (BMRN) is expected to report $0.28 for Q3 2023

2023-10-23 16:05:17 ET More on BioMarin Pharmaceutical BioMarin: Growth Drivers Remain Intact BioMarin: Q2 2023 Confirmed My Bullish View Biomarin Pharmaceutical, Inc. (BMRN) Q2 2023 Earnings Call Transcript FDA approves use of BioMarin drug Voxzogo in childr...

2023-10-20 17:21:59 ET More on BioMarin Pharmaceutical BioMarin: Growth Drivers Remain Intact BioMarin: Q2 2023 Confirmed My Bullish View Biomarin Pharmaceutical, Inc. (BMRN) Q2 2023 Earnings Call Transcript BioMarin a market perform at Raymond James due to g...

U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia PR Newswire Expanded Indication in the U.S. Now Includes Children of all ages with Achondroplasia SAN RAFAEL, Calif. , Oct. 20...